AUG 17·SEC EDGARLow
BARNETTE K GARY purchased $5K of VERU
BARNETTE K GARY (Chief Scientific Officer) purchased 1,800 shares of VERU INC. (VERU) at $2.69 on 2026-08-13.
StockNASDAQ · US · USDHealthcare · Biotechnology
$VERU
VERU INC.
Price · $VERUvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $VERU in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $VERU in the last 30 days.
See all $VERU insider activity →Top stories · $VERUMore →
AUG 10·quiverquant.com
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239
Veru Inc. (VERU) reported fiscal 2026 Q3 results ended June 30, 2026, with a net loss of $7.0 million, or $0.30 per share. The Phase 2b PLATEAU trial of enobosarm plus semaglutide is fully enrolled with 239 patients. Interim analysis is expected in Q1 2027, final topline in Q4 2027. Cash was $23.9 million.
AUG 10·SEC EDGAR 8-K
VERU INC. (VERU): Results of Operations and Financial Condition
VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl
VERU sentiment & insider activity
Recent VERU coverage spans financial news, earnings and insider activity.
What's driving VERU
This is an insider open-market purchase, which can be read as confidence but is not a fundamental catalyst by itself.
Enrollment completion and ongoing interim readout timing reduce trial execution risk, but the reported net loss and cash level keep financing and burn-rate risk in focus.
Near-term catalyst is the planned Q1 2027 interim analysis; today’s filing adds enrollment completion, Novo Nordisk supply agreement, and USPTO notice of allowance.
Lower G&A expense helped narrow the Q3 net loss, which can improve near-term profitability optics even if revenue or operating performance is unchanged.
Conference participation itself is not a fundamental catalyst, but the reiterated clinical timeline and study design can influence near-term sentiment around enobosarm’s obesity program.
AlphAI scores every news story that mentions VERU with an AI model for sentiment and relevance, and aggregates insider trades from VERU INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $VERU
Score
BARNETTE K GARY purchased $5K of VERU
BARNETTE K GARY (Chief Scientific Officer) purchased 1,800 shares of VERU INC. (VERU) at $2.69 on 2026-08-13.
1 min read
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239
Veru Inc. (VERU) reported fiscal 2026 Q3 results ended June 30, 2026, with a net loss of $7.0 million, or $0.30 per share. The Phase 2b PLATEAU trial of enobosarm plus semaglutide is fully enrolled with 239 patients. Interim analysis is expected in Q1 2027, final topline in Q4 2027. Cash was $23.9 million.
4 min readVERU INC. (VERU): Results of Operations and Financial Condition
VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl
6 min readVeru Q3 net loss narrows on lower G&A expenses
Veru reported Q3 results in which its net loss narrowed, attributing the improvement to lower general and administrative (G&A) expenses, according to the company. The article focuses on the change in costs and the resulting earnings performance for the quarter.
1 min read
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Veru Inc. (NASDAQ: VERU) said it will present at the 2026 Obesity & Weight Loss Drug Development Summit in Boston (July 14–16, 2026). The company’s CEO Mitchell Steiner will discuss combining GLP-1s with SARMs to address sarcopenic obesity. Veru also outlined its Phase 2b PLATEAU enobosarm+semaglutide study (about 200 older patients), with interim analysis expected at 32 weeks in 1Q 2027 and topline data in 4Q 2027.
2 min readVERU INC. (VERU): Entry into a Material Definitive Agreement
VERU INC. (VERU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 d124945dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Veru Inc. Shares of Common Stock (par value $0.01 per share) Sales Agreement July 2, 2026 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Canaccord Genuity LLC Penn 1, One Pennsylvania Plaza, Suite 2900 New
4 min read
Contrasting Veru (NASDAQ:VERU) & Boston Scientific (NYSE:BSX)
The article compares Veru (NASDAQ:VERU) and Boston Scientific (NYSE:BSX) across profitability, risk, earnings, valuation, analyst targets, and ownership. It says Boston Scientific has higher institutional ownership (89.1% vs 47.2%) and lower insider ownership (0.3% vs 14.2%). Veru’s beta is -1.19 vs BSX 0.62. Analyst consensus targets are $23.00 for Veru and $92.71 for BSX. It also notes BSX has higher revenue and earnings, while Veru trades at a lower P/E.
5 min read
Veru tests add-on pill to preserve muscle during Wegovy weight loss
Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial, investigating enobosarm in combination with semaglutide (Wegovy) for high-quality weight loss in older obese patients. The study aims to preserve lean mass, physical function, and bone while augmenting fat loss. Interim data is expected in Q1 2027, with final topline data anticipated in Q4 2027.
3 min read
Veru to Present Two Abstracts at ObesityWeek 2025 - Veru (NASDAQ:VERU)
MIAMI, FL, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ:VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek ...
3 min readOnconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
CINCINNATI, OH, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ( Nasdaq: ONCO ) ( "Onconetix" or the "Company" ) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the ...
3 min read